GVK Biosciences and Onconova Therapeutics has signed a pact to develop new drugs for cancer. The pact will facilitate to move oncology assets from Ocnonova Therapeutics to GVK discovery platform from early discovery to clinical development stage. As per the pact, Ocononova will provide two discovery targets for development of new drugs.
MSD, a unit of Merck Ltd is planning to set up a lab for developing vaccines in joint venture with Wellcome Trust Hilleman Laboratories (the Hilleman Labs - a London based research charity) in India. It will come up at Delhi Jamia Millia Islamia University campus and will entail an investment of USD 150 million. MSD has already developed a vaccine for rotavirus which has 90% efficiency against severe gastroenteritis. The lab will focus on vaccines for disease prevalent in tropical countries